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Autologous cell therapies are currently being evaluated in multiple clinical trials and 
are becoming a reality in advanced healthcare services. Compared to allogeneic cell 
therapies, where one batch of cells can be used to treat multiple patients and which 
allows a business model that is more closely related to the traditional biologics, au-
tologous or patient-specific cell-based therapies present a whole new set of chal-
lenges. While these new challenges can originate from ethical issues (e.g., concerns 
about the patient in cases of batch failure) or from safety concerns (e.g., cross-con-
tamination between patients), this article provides an overview of the technical side 
of cell-therapy manufacturing that is subject to donor-related variability. Although 
several studies have managed to produce batches of cells with a scale that satisfies 
therapeutic needs, there are still a number of challenges that need to be tackled. 
Unlike traditional manufacturing processes where the input material is relatively 
constant over time, personalization aspects inherent to the autologous reality will 
expose manufacturing to significant variability and production risks. The authors 
argue that for autologous cell production, where every patient-specific production 
batch can be considered as an unknown process, a combination of automated pro-
duction processes and robust process monitoring & control capabilities can provide 
quantitative process understanding. At a second stage, provided large data becomes 
available through (on-line) data-based process analytics, minimized risk and cost-ef-
fective cell production for clinical use will become a reality.
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Autologous cell therapy focuses on 
bioprocesses that allow a patient’s 
own cells to be manufactured into 
an advanced therapy medicinal 
product (ATMP). The major advan-
tage of autologous cell therapies is 
that the implanted cells will not trig-
ger a graft-vs-host immune response 
thus reducing the need for immu-
nosuppression. Therefore in autol-
ogous therapy, production batches 
are expected to be patient-specific 
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whereby the ATMP is used only for 
that patient. Compared to allogene-
ic treatments, where a production 
batch serves multiple patients, the 
autologous manufacturing strategy 
inherently possesses specific chal-
lenges that are attributed to limited 
economies of scale, risks associated 
to batch failure, bioprocess flex-
ibility and production planning. 
A subdivision of autologous AT-
MPs are mesenchymal stromal cell 
(MSCs)-based products. More than 
400 clinical trials use currently hu-
man mesenchymal stromal cells as 
a therapeutic cell source   [1,2], the 
growth and potential benefits that 
can be brought by cell-based ther-
apy seems to be recognized by in-
dustry. Consequently, more and 
more cell-based companies arise 
leading in a substantial growth of 
the field which moves towards a 
distinct sector of the healthcare in-
dustry  [3,4]. Currently, a challenge 
that has been faced by the emerging 
ATMP industry is the preparation 
of cell -based ATMPs under “hos-
pital expemption” as an alternative 
regulatory pathway towards the 
patient. Also in combination with 
high costs required for GMP man-
ufacturing and maintenance, hos-
pital exemption has been linked to 
the the very low percentage of trans-
lation from academic development 
of ATMPs towards regular clinical 
care  [5]. Through this specific reg-
ulatory pathway ATMPs can reach 
patients earlier and without having 
to go through the cumbersome pro-
cess of getting the cell product to 
commercial scale [6]. An addition-
al complication in the European 
Union is the existence of big regu-
latory differences among member 
states regarding hospital expemt-
pion and GMP manufacturing in 
hospital settings [7]. The alliance 
for advanced therapies (AAT) has 
emphasized that the inconsistent 
implementation of the hospital ex-
emption in the EU member states 
and routine preparations of treat-
ments under an exemption impede 
the development of new safe and 
cost-effective treatments  [8].
It is expected that most autolo-
gous cell therapy applications batches 
should be able to deliver cell numbes 
ranging between 106 and 109 cells for 
a single dose [9,10]. The adoption of 
monitored and controlled bioprocess-
es that are able to guarantee the pro-
duction of cell-based therapies with 
manageable cost of goods (COGs) 
and robust in vivo performance  [11–
14] has been identified as an important 
prerequisite to address the currently 
low number of Phase III clinical tri-
als translated into viable commercial 
products. Upstream challenges have 
been to date addressed in terms of the 
quantities of cells that need to be pro-
duced. Bioreactors have been increas-
ingly tested in large volumes and used 
for ATMP production due to the fact 
that they provide an improved cell 
culture environment by controlling 
nutrient refreshment and waste re-
moval rates  [15], flexibility in scale of 
operation, while reducing bioprocess 
complexities  [16]. The use of biore-
actor systems with various designs 
for the expansion of human MSCs 
is a reality and is by now adopted for 
industrial production, reflecting that 
major concerns regarding large-scale 
MSC production are addressed. This 
is indicated by an increasing number 
of recent review papers  [17–19] in-
cluding successes in MSC expansion 
in academic, hospital and industrial 
settings [20]. However, extensive in-
vestigation of downstream processes 
such as centrifugation and filtration 
and vialing has only recently been 
carried out. 
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SOURCES OF VARIA-
TION FOR MSC-BASED 
BIOPROCESSING
Existing literature and regulato-
ry perspectives [21] discuss a very 
broad number of parameters that 
should be taken into account when 
designing bioprocesses for the ex-
pansion of MSC populations. These 
factors should be classified as sourc-
es of variability and could all affect 
bioprocess efficiency and result. 
Below is a list and breakdown of 
possible sources of variation during 
MSC-based manufacturing:
Donor profile is a major source 
of variability in autologous MSC 
therapy since the donor to donor 
difference can be linked not only to 
the genetic profile of each patient 
but also to factors such as disease 
and life style  [22]. In addition, do-
nor-related variability can affect 
not only the final product charac-
teristics, but also in-process perfor-
mance and sensitivity to bioreactor 
operating parameters. Accordingly, 
process screening and optimization 
experiments should include basic 
characterization of donor sensitivity 
to process parameters  [22]. 
Most commonly used cell types 
are bone marrow [23], umbilical 
cord [24], adipose [25], synovi-
um  [26] and periost  [27]. An autol-
ogous specific challenge is that MSC 
numbers harvested from biopsies 
differs because of the way biopsies 
are obtained by clinicians. In addi-
tion, tissue specific biopsies contain 
different fractions and numbers of 
true progenitor cells. For example 
1 mL of human MSCs from the 
bone marrow results approximate-
ly in 103 MSCs  [28]. On the other 
hand, adipose-derived MSCs count 
for 0.5–2.0 × 106 cells/g of adipose 
tissue. From these cell numbers the 
percentages of MSCs range from 1 
to 10%  [29]. As illustrated there 
is not only an inherent interdonor 
variability but also an intradonor 
variability in the basic “raw materi-
al” of the autologous paradigm. 
A large range of culture setups 
used to support MSC expansion 
contributes to donor specific bio-
process efficiency and variability. 
For instance microcarrier-based 
stirred tank reactors [30], hollow 
fiber [31], wave bags  [32] and mul-
tiplate bioreactors [33] have been 
successfully employed to generate 
large-scale batches of MSCs for au-
tologous applications. In addition, 
donor responses to culture plastic, 
and by extension any culture sur-
face in general, itself can potentially 
induce variability in cell yields  [34].
There is a large variety of cus-
tomized media formulations for cell 
expansion, entailing for example 
different protein sources or glucose 
concentrations. Media contain-
ing non-defined sources of protein 
such as Fetal Bovine Serum (FBS) 
and Human Platelet Lysate (HPL) 
expose ATMP manufacturing to 
batch-dependent process variabili-
ty. Moreover they pose a consider-
able risk for pathogen transmission. 
Due to this, great effort is focused 
in the development of chemically 
defined xeno-free media that would 
allow efficient and controlled MSC 
growth  [35,36]. An overview of se-
rum-free media available for MSC 
expansion can be found in  [37]. Fi-
nally, cryopreservation media used 
to freeze products (in cases where 
transport to the patient is required) 
could also affect in a different way 
cells from different donors.
Bioprocess operating conditions, 
for instance cell seeding densities 
per passage, media refreshment 
strategies, response to shear type 
and magnitude, perfusion rates and 
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dissolved oxygen tension, vary for 
almost every process  [38] and could 
affect process performance in a do-
nor related context  [39].
The aforementioned parameters 
reveal that autologous MSC expan-
sion and product development is an 
extremely complex and challenging 
bioprocessing endeavour. In addi-
tion, constantly changing metrics 
for bioprocess characterization have 
been to date employed to quantify 
bioprocess efficiency. This results in 
incomparability between investiga-
tions based on the reported results 
requiring substantial data postopro-
cessing. For instance the calculation 
of “population doubling time” and 
“fold increase” obtained as a metric 
after a cell expansion process differs 
between report, sometimes starting 
from a theoretical seeding density 
or an estimate of the successfully 
seeded/attached number of cells in 
a bioreactors system  [36]. 
We would like to stress the need 
for critical and systematic analysis 
of existing information that could 
result in: (i) process comparability 
(ii) process benchmarking (iii) im-
proved understanding of bioprocess 
efficiency (iv) risk assessment, all re-
sulting in rational design of whole 
autologous bioprocesses. 
ON QUALITY CONTROL & 
PRODUCT COMPARABILITY
A major challenge that needs to 
be addressed by cell-based ATMP 
manufacturers is to demonstrate 
and maintain product comparabil-
ity after changes have been intro-
duced in the bioprocess  [40]. This 
is expected to occur as bioprocesses 
involved in product manufactur-
ing are optimized or altered. This 
is expected for instance to occur 
when moving from a 2D to a 3D 
platform for MSC culture or when 
automation is introduced in the 
manufacturing line   [41]. There-
fore, assays ensuring product qual-
ity and allowing proof of product 
comparability, establishing prod-
uct safety and efficacy, are re-
quired. However, in the field there 
is increasing concern even on the 
use of the generic term “Mesenchy-
mal Stromal Cells (MSCs)” which 
has been used as an umbrella term 
encompassing multiple progenitor 
populations derived from a vari-
ety of sources  [42]. To characterize 
these cells, to date, a minimal set of 
criteria where suggested from the 
International Society of Cell Ther-
apy (ISCT) comprising of adhesion 
to plastic, several CD markers and 
in vitro differentiation tests  [43] 
and have since been extensively 
adopted as proof of multipotency 
of an “MSC” population. However 
we should emphasize that current-
ly, no single-cell surface marker 
is available for the unambiguous 
identification of MSCs. In addi-
tion these metrics do not reflect 
the identity or potency of MSC 
populations. A recent report re-
vealed that committed progenitors 
of distinct origin (that would all 
be characterized as MSCs) where 
characterized by in vivo bone form-
ing assays  [44]. Moreover, pericytes 
from different sources (cell types 
under the generic term MSCs) 
seem to exhibit remarkably differ-
ent behavior and differentiation 
potential  [45]. 
Therefore the discovery of qual-
ity controls of higher biological 
specificity and discriminative pow-
er that would also link to cell po-
tency are urgently needed. Ideally 
these metrics should be also linked 
to the mechanism of action of the 
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harvested and expanded progenitor 
cell populations. New technolo-
gies for epigenetic analyses of cells 
could provide important informa-
tion regarding the classification of 
types  [46] based on their tissue of 
origin even after extensive culture, 
and about bioprocessing during dif-
ferentiation of MSCs and its impact 
on epigenetic patterns  [47]. The 
generation of specific epigenetic 
signatures reflects functional prop-
erties of MSCs such as their hema-
topoiesis supportive function  [48]. 
Epigenetic signatures could be also 
developed in order to evaluate the 
therapeutic potential of MSCs after 
validation with suitable datasets.
Variation in starting materials 
is a significant challenge and the 
ability within the field to quanti-
fy and potentially control it will 
require the adoption of systemat-
ic and quantitative metrics as al-
ready mentioned. Potential ways 
of defining bioprocessisng metrics 
could be carried out and even the 
adoption of reference MSC lines 
has been suggested as a calibration 
tool  [49,50]. In addition, knowl-
edge on the impact of manufac-
turing at different sites on MSC 
product quality is still rather lim-
ited and should be explored as 
this model of production would 
rely on such production and dis-
tribution strategies. In a recent 
study eight centers carried out 
manufacturing of BMSCs for ear-
ly phase clinical trials following 
Good Manufacturing Practice 
(GMP). They observed substantial 
differences between locations in 
both the in vitro properties of the 
cells as well as their performance 
in vivo in terms of bone forma-
tion and bone marrow formation 
on ceramic carriers exhibiting low 
comparability across sites  [51]. 
RISK ASSESSMENT & 
MANAGEMENT
The application of risk assessment 
has been mostly applied to auto-
mated processes, as for instance 
the ones encountered in the bio-
pharma industry. However in the 
case of the autologous MSC based 
production, which is to date high-
ly dependent on manual interven-
tion, this poses considerable chal-
lenges. A number of such tools 
have been employed such as risk 
ranking, hazard analysis and criti-
cal control points (HACCP), haz-
ard operability analysis and failure 
mode and effects analysis (FMEA) 
which allow highlighting of po-
tential errors and define actions to 
perform to prevent consequenc-
es. In addition, more quantitative 
approaches, such as the failure 
modes effects and criticality analy-
sis (FMECA) that quantify errors, 
could be also implemented in the 
field for managing these risks when 
moving to translational setting. 
Risk assessment for autologous 
processes becomes more complex 
due to for instance donor variabil-
ity, e.g. the donor-specific popula-
tion doubling times require higher 
flexibility for production planning, 
multiple sources of donor material 
might increase the chance of con-
tamination, donor-related lot-to-
lot variability complicates the use of 
classical statistical process control 
techniques (e.g., control charts and 
process capability analysis  [52]. 
Stochastic modelling techniques 
such as Monte Carlo simulations 
and risk-based analysis could help 
to gain more insight on the impact 
of these sources of variation on the 
production process  [53]. 
Only a handful of studies 
demonstrate the adoption of risk 
management tools for cell therapy 
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manufacturing and these examples 
comprise of liver progenitor and 
chondrocyte cells. An example of 
adoption of a failure mode and ef-
fects analysis (FMEA) can be seen 
in Lopez et al  [54] whereby risks 
were identified and prioritized 
and a severity/occurrence matrix 
was highlighted for the produc-
tion of liver progenitor cells. In 
another study it was shown that 
the implementation of an FMEA/
FMECA method revealed the cau-
sality of human errors (either due 
to errors or inadequate training) 
and the subsequent introduction 
of 26 criticalities within GMP 
production of autologous chon-
drocyte implantation [55]. Cur-
rently, a major challenge in the 
field for the implementation of 
similar approaches is the absence 
of  reference standards for deter-
mining acceptable risk levels and 
this should be further explored.
Since the field is currently ex-
panding both in terms of MSC-
based products but also in terms 
of novel automated bioprocesses 
supporting cell expansion (multiple 
bioreactor types), cell separation, 
condensation and fill and finish 
and freezing steps, similar strategies 
could be followed during their in-
tegration and adoption in the pro-
duction pipeline. Risk assessment 
for the determination of critical 
quality attributes of the MSC-based 
product should be carried out for 
each bioprocess step. Similarly the 
classification of the most influential 
process parameters of each biopro-
cess on its performance as well as 
that of material attributes (for the 
MSC case donor related and also 
niche/origin related) should be also 
carried out. Currently there is limit-
ed literature on this topic for MSC 
based bioprocesses.
Considering cost-effective-
ness during bioprocess design
The integration of process perfor-
mance with cost estimates requires 
the maintenance of several culture 
parameters across culture systems. 
As this is rather a challenging en-
deavour only limited information 
is currently available. For an autol-
ogous example this was carried out 
for multiple standardized large-scale 
expansion processes and reported 
recently by Lambrechts et al  [56]. 
The calculation compared the ex-
pansion of 20 million MSC-like 
cells (human periosteum derived 
progenitor cells] to 350 million 
cells in high-glucose DMEM sup-
plemented with 10% irradiated 
FBS in T175 tissue culture flasks, 
a hollow fiber bioreactor (Terumo 
BCT Quantum® Cell Expansion 
System, [57]) a multiplate bioreac-
tor (Pall Integrity Xpansion, [33]) 
and in a spinner flask with Cul-
tiSphere-S microcarriers (unpub-
lished results). The general conclu-
sion here was that for this relatively 
smaller scale (autologous case study) 
the microcarrier-based expansion 
process is most likely to result in the 
lowest production costs, while the 
ease of use of the hollow fibre and 
multi-plate bioreactor is offset by a 
high cost of the disposable materi-
als. However this was based on cur-
rent values and expenses that could 
gradually change and adapt to a 
growing cell therapy market.
Similar results can be found for 
large-scale (allogeneic) expansion 
processes. For example, the eco-
nomics of allogeneic expansion for 
pluripotent stem cells (iPSCs and 
ESCs) have been recently modeled 
and described both for the up-
stream  [58] as well as for the subse-
quent downstream operations  [59]. 
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This is not yet clearly addressed in 
the case of autologous large-scale ex-
pansion, where most likely a generic 
solution does not exist and optimal 
solutions will be case specific, based 
on inherent cell or donor properties 
as well as practical limitations (e.g. 
cells obtained from biopsies vs. cells 
required for therapy)  [12]. Addi-
tionally, the cost of quality control 
requires more specific attention in 
these process models, since the ad-
ditional cost per dose is weighing 
more on the autologous case be-
cause of the lack of economies of 
scale. Due to the inherent donor-re-
lated variability and uncertainty in-
volved in these processes, the use of 
such deterministic models for the 
autologous case would therefore be 
a challenging task.
SCALABILITY OF MSCS
The discussion regarding scalability 
for autologous and allogeneic cell 
production on the basis of “scale-
out” or “scale-up” has by today 
clarified best practice for each case. 
While scale-out is simply carrying 
out numerous same and “smaller” 
scale bioprocesses (parallelisation 
of processes with the same dimen-
sions), scale-up envisions a direct 
increase in volume or surface of the 
culture. For autologous expansion 
processes, the production strate-
gy of choice is not yet carved in 
stone. The available bioreactor cul-
ture scale must take into account 
the flexibility to accommodate the 
range of cell growth across all batch-
es and also the fact that doses might 
also differ based on patient profile, 
i.e. personalized dosing. A number 
of systems exist in the market offer-
ing GMP-grade such as the hollow 
fibre system by Terumo (Quantum) 
and the Xpansion series by Pall both 
allowing to reach batches of 5x108 
cells suitable for multiple autol-
ogous applications. A bottleneck 
in the adoption of these systems is 
the high number of cells needed for 
seeding 10-20x106 cells which is 
much higher than the cell number 
obtained from biopsies. Therefore a 
2D culture step would be needed to 
reach the required number of MSCs 
for bioreactor seeding. In addition, 
suspension bioreactors (i.e., Xuri 
and PBS biotech) with microcarri-
ers allow a high degree of flexibility 
in terms of scale, crucial for the au-
tologous case study. 
In addition we would like to also 
stress the cost efficiency of biore-
actor systems especially when the 
manufacturing footprint comes into 
the picture allowing for more com-
pact platforms for product delivery 
requiring less personnel to carry 
out manufacturing  [60]. The use of 
monitored and controlled bioreac-
tors allows process automation (e.g. 
automated liquid transfer steps), 
which in turn achieves a reduc-
tion in labor requirements as well 
as improvements in quality assur-
ance. Together, these steps serve not 
only to reduce the cost for patient 
specific manufacturing, but also to 
allow scale-out strategies whereby 
multiple batches are simultaneously 
manufactured, potentially in multi-
ple non-centralized facilities. Fur-
ther, the increased control afforded 
by bioreactors serves to reduce the 
risk of batch failures through ear-
ly fault detection, efficiently using 
scarce donor materials and reducing 
the time patients wait for a therapy. 
Additionally, the more individual-
ized process of which the produc-
tion is often aimed to take place 
close to the bedside of the patient 
(distributed manufacturing) seems 
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to require more integrated systems, 
where cell expansion, volume re-
duction and cell sorting are en-
closed in one automated device (e.g. 
the Octane Cocoon bioreactor and 
Miltenyi Biotec’s Prodigy). These 
versatile and low footprint compact 
devices could also be adopted for 
point of care manufacturing within 
hospital facilities, which could be a 
second strategy for manufacturing 
autologous MSC-based ATMPs in 
contrast to a more centralized man-
ufacturing model  [60].
DOWNSTREAM BIO-
PROCESSES & PROCESS 
INTEGRATION
The production of MSCs for au-
tologous therapy and especially 
the “upstream” component of the 
whole-bioprocess has been inves-
tigated thoroughly, dealing with 
scalability and GMP aspects. How-
ever, in order to consider whole-bi-
oprocess design there needs to be 
equal attention and effort on the 
development of efficient and flexi-
ble downstream bioprocesses. More 
particularly, the new generation of 
downstream processes should be 
able to address the increasing vol-
umes and batches of cells produced 
at the upstream stages, but also 
possess flexibility in operation for 
supporting numerous autologous 
expansion processes. For instance, 
MSC harvest from microcarriers in 
suspension bioreactors was recent-
ly investigated providing a scalable 
methodology [61], while in a follow 
up study the authors linked this pro-
cess to the subsequent cryopreserva-
tion step  [36,61]. Dynamic harvest 
of single cells from fixed bed biore-
actors was also recently described 
for the recovery of periost derived 
progenitor cells which retained 
their bone froming potential in 
vivo [62]. Downstream operations 
are becoming of significant impor-
tance for stem cell bioprocessing, 
and initial theoretical discussions 
on separation techniques possibly 
useful for the cell therapy field as re-
viewed by Diogo et al.  [63] are be-
coming a reality. There is a growing 
rate of studies on bioprocesses and 
methods required for the clarifica-
tion and volume reduction of MSC 
suspensions using membranes and 
tangential  [64,65] or dead-end  [66] 
filtration. Established techniques 
in other biotechnological fields are 
also successfully adopted such as 
the use of expanded bed chroma-
tography for the washing of MSC 
suspension resulted in improved ef-
ficiency  [67]. This shows the rapid 
evolution of the field in reaching 
a pipeline of unit operations for 
(autologous) MSC manufacturing, 
customized per application and 
from patient-to-patient.
Making use of scale-down au-
tologous bioprocess pipelines
Given the high-risk associated with 
autologous bioprocesses, scale down 
methodologies are needed for quan-
tifying and exploring the complexi-
ties of personalized bioproduction. 
The evaluation of potentially opti-
mal windows of bioprocess oper-
ation could suggest similar culture 
conditions for larger scale formats 
provided proper scaling parameters 
are used. Although commercially 
systems are available for suspen-
sion culture, the volumes used are 
still in the order of magnitude of 
10s of millilitres. We believe that 
there is room for pursuing the de-
velopment of mini bioreactors that 
allow a further scale-down, while 
in parallel increase throughput. 
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Reichen et al  [68] have shown that 
the quantification of cell specific 
attributes can be measured in high 
throughput microfluidic devices, 
however the behaviour of cells on 
flat surfaces may not be necessar-
ily predictive of that on surfaces 
possessing curvature such as for in-
stance on microcarriers. Shear stress 
is a factor that can be encountered 
in multiple units of operation from 
impeller shear to acute capillary 
shear during flow through orifices 
and capillaries. The impact of such 
shear magnitudes on cells destined 
for cell therapy has been carried 
out in small (µL) volumes [69,70] 
showing that fluid flow conditions 
could be fine-tuned to minimizing 
cell loss and cell property degener-
ation. Scale down strategies aim-
ing to mimic the effects of specific 
downstream processes were also re-
cently shown by Delahaye et al  [71] 
for dead-end centrifugation, and 
by Masri et al  [72] for a membrane 
separation and recovery bioprocess. 
We could therefore suggest that 
such scale down tools could provide 
a first solid basis for evaluating opti-
mal bioprocess integration scenario 
at a low cost and low risk environ-
ment. Moreover the production of 
low-cost high-throughput time se-
ries data sets could also be achieved 
helping considerably in uncertainty 
quantification capturing potentially 
similar trends with the large scale 
units of operation.
RATIONAL DATA-BASED 
BIOPROCESS DESIGN
A growing discussion on standard-
ization, given the large variety of 
complex components involved in 
cell therapy research and develop-
ment  [73], highlights that its absence 
is an obstacle for the transition of 
autologous cell-based therapeutics 
from the development phase that 
is often based on trial and error, to 
the translational stage that requires 
robust and cost-effective process-
es  [74]. For instance, the adoption 
of improved standards for cell-
based ATMPs entering clinic  [75] 
was recently suggested. Regarding 
input cell material, recent literature 
has highlighted the need for stan-
dardized MSC lines as calibration 
tool  [49] or reference material  [76] 
while a systematic data-based ap-
proach and centralized manufac-
turing facilities able to conduct sys-
tematic comparability studies was 
advocated by McKenna et al.  [77], 
highlighting the invasiveness of the 
immortalization step to the initial 
cell properties. Moreover, in order 
to address the complex regulatory 
landscape, a cell therapy regulatory 
toolkit (online regulatory resource) 
was introduced for new ATMPs en-
tering clinical trials for the EU and 
USA  [78]. It is clear that a certain 
degree of standardization would be 
helpful to move the field forward, 
however many cell-based therapies 
(in particular autologous therapies) 
will require personalized approaches 
where flexibility is required in order 
to allow customization per patient 
or per therapy. 
FUTURE CHALLENGES
The lack of quantitative under-
standing of a series of factors that 
would enable rational bioprocess 
design and risk minimization is 
still a major threat in establishing 
viable production lines. The call 
for inclusion of process analytical 
technology (PAT) tool in cell thera-
py biomanufacturing is much more 
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crucial in the autologous case. We 
believe that the incorporation of 
data based tools, that are able to 
treat time-series data from diverse 
bioprocesses and automatically pro-
viding quantitative metrics for each 
bioprocess, could be a first consid-
erable step to personalized autolo-
gous biomanufacturing pipelines. 
Time series of process parameters 
that quantitatively describe the 
dynamic culture environment [79] 
could provide much more insight-
ful information on the dynamics as 
well as the robustness of autologous 
bioprocesses. 
While for most process control 
strategies on-line measurements of 
specific Critical Quality Attributes 
(CQAs) are required, this is not al-
ways feasible in the autologous case. 
From a practical point of view, the 
limited donor material does not al-
low for frequent (destructive) sam-
ple taking during culture, while 
the comparability of very specific 
CQA measurements (e.g. by mass 
spectrometry or ELISA) is chal-
lenging in the often distributed 
manufacturing facilities. From a 
cost perspective, an expensive CQA 
measurement is much more detri-
mental for the cost-effectiveness of 
an autologous strategy compared 
to an allogeneic strategy where this 
cost can be distributed over multi-
ple patients. Model-based monitor-
ing and control strategies, where a 
combination of multiple (easy to 
measure) process parameters such 
as metabolite consumption and 
oxygen uptake are combined with 
a predictive model that allows to 
estimate the state of a CQA are 
therefore a promising strategy for 
the cost-effective production of au-
tologous therapies  [80].
Future challenges will also lie on 
the identification of more specific 
CQAs. Although the ISCT criteria 
provide minimum cell identifica-
tion criteria  [43], it would be cru-
cial for autologous processes to be 
linked to potency assays. This will 
be a major challenge as increased 
sensitivity and functionality CQAs 
would be cell type and application 
specific. Currently there is minimal 
information in literature describing 
and linking the performance of ex-
panded autologous cells in in vivo 
settings. This info, which is usually 
omitted and only seldom linked to 
its bioprocess history, would prove 
that expanded cells where actually 
potent and useful for clinical appli-
cation. The need for such predictive 
potency assays, linking the process 
in  vivo activity and defining actu-
ally the critical process parameters, 
would also ensure product compa-
rability during subsequent manu-
facturing phases  [81]. 
CONCLUSION
The steady increase in MSC pro-
duction scales demonstrates the 
continuous maturation of the field. 
However, mainly for autologous 
therapies, there are considerable 
bioprocess engineering challenges 
to be faced for the successful tran-
sition from early preclinical to late 
commercial stage manufacturing. 
A major factor contributing to this 
challenge is the donor-related vari-
ability in combination with the fact 
that there is no typical, one-size-fits-
all manufacturing solution. Metrics 
allowing the identification of MSC 
progenitor subpopualtions and 
added markers predicting potency 
are necessary for comparability and 
technology transfer endeavours. 
Further understanding basic biol-
ogy and mechanism of action of 
EXPERT INSIGHT 
479Cell & Gene Therapy Insights - ISSN:2059-7800 
MSC-based therapeutics and the 
implementation of novel technol-
ogies for quantifying this is also 
needed. Th e implementation of risk 
assessment and management strat-
egies will also allow translating the 
fi eld to a mitigated manufacturing 
fi eld ready to address current clinical 
needs. Th e development of product 
and process specifi c data-signatures 
derived from the incorporation of 
sensors in all bioprocess steps, could 
help in increasing our understand-
ing of dealing with personalized 
biomanufacturing. 
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